Geron Announces Layoffs, Cutting One-Third of Staff

Geron is laying off one-third of its workforce as part of a strategic realignment to focus on the commercial launch of its drug, Rytelo. The move is intended to streamline operations and ensure a successful market introduction for the new treatment.